ClinicalTrials.govrestricted
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04203485. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 12
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 8